NO20053431L - Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid. - Google Patents

Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.

Info

Publication number
NO20053431L
NO20053431L NO20053431A NO20053431A NO20053431L NO 20053431 L NO20053431 L NO 20053431L NO 20053431 A NO20053431 A NO 20053431A NO 20053431 A NO20053431 A NO 20053431A NO 20053431 L NO20053431 L NO 20053431L
Authority
NO
Norway
Prior art keywords
phenyl
methyl
dioxo
pyridin
trifluoromethyl
Prior art date
Application number
NO20053431A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053431D0 (no
Inventor
Torsten Hoffmann
Fabienne Hoffman-Emery
Sonia Nick
Urs Schwitter
Pius Waldmeier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20053431D0 publication Critical patent/NO20053431D0/no
Publication of NO20053431L publication Critical patent/NO20053431L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20053431A 2003-01-31 2005-07-14 Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid. NO20053431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002134 2003-01-31
PCT/EP2004/000547 WO2004067007A1 (en) 2003-01-31 2004-01-23 NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE

Publications (2)

Publication Number Publication Date
NO20053431D0 NO20053431D0 (no) 2005-07-14
NO20053431L true NO20053431L (no) 2005-10-05

Family

ID=32798734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053431A NO20053431L (no) 2003-01-31 2005-07-14 Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.

Country Status (28)

Country Link
US (1) US7160881B2 (de)
EP (1) EP1592428B1 (de)
JP (1) JP5026702B2 (de)
KR (1) KR100700421B1 (de)
CN (1) CN100562320C (de)
AR (1) AR042980A1 (de)
AT (1) ATE366576T1 (de)
AU (1) AU2004208483B8 (de)
BR (1) BRPI0406702A (de)
CA (1) CA2514037C (de)
CL (1) CL2004000150A1 (de)
CO (1) CO5580750A2 (de)
DE (1) DE602004007486T2 (de)
ES (1) ES2290666T3 (de)
GT (1) GT200400009A (de)
HR (1) HRP20050664A2 (de)
IL (1) IL169600A (de)
MX (1) MXPA05008171A (de)
MY (1) MY135785A (de)
NO (1) NO20053431L (de)
NZ (1) NZ541243A (de)
PA (1) PA8594601A1 (de)
PE (1) PE20040944A1 (de)
PL (1) PL378404A1 (de)
RU (1) RU2330022C2 (de)
TW (1) TWI293294B (de)
WO (1) WO2004067007A1 (de)
ZA (1) ZA200505567B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776342B1 (de) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
JP2013503134A (ja) * 2009-08-27 2013-01-31 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 無水形態のピリジン誘導体
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69428913T2 (de) * 1993-12-29 2002-05-29 Merck Sharp & Dohme Ltd., Hoddesdon Substituierte morpholinderivate und ihre verwendung als arzneimittel
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
MXPA03009720A (es) * 2001-04-23 2004-01-29 Hoffmann La Roche USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
PL378404A1 (pl) 2006-04-03
CN1744900A (zh) 2006-03-08
EP1592428B1 (de) 2007-07-11
HRP20050664A2 (en) 2006-12-31
CA2514037A1 (en) 2004-08-12
US20040186100A1 (en) 2004-09-23
IL169600A (en) 2010-11-30
ATE366576T1 (de) 2007-08-15
AR042980A1 (es) 2005-07-13
PE20040944A1 (es) 2004-12-14
ZA200505567B (en) 2007-05-30
BRPI0406702A (pt) 2005-12-20
CL2004000150A1 (es) 2005-01-07
CN100562320C (zh) 2009-11-25
KR20050096964A (ko) 2005-10-06
MXPA05008171A (es) 2005-10-05
TWI293294B (en) 2008-02-11
CO5580750A2 (es) 2005-11-30
NZ541243A (en) 2008-04-30
US7160881B2 (en) 2007-01-09
AU2004208483A1 (en) 2004-08-12
NO20053431D0 (no) 2005-07-14
DE602004007486T2 (de) 2008-04-30
RU2005127216A (ru) 2006-04-10
EP1592428A1 (de) 2005-11-09
MY135785A (en) 2008-06-30
ES2290666T3 (es) 2008-02-16
AU2004208483B8 (en) 2008-04-03
KR100700421B1 (ko) 2007-03-28
JP2006514999A (ja) 2006-05-18
DE602004007486D1 (de) 2007-08-23
RU2330022C2 (ru) 2008-07-27
TW200510358A (en) 2005-03-16
JP5026702B2 (ja) 2012-09-19
WO2004067007A1 (en) 2004-08-12
CA2514037C (en) 2012-03-13
GT200400009A (es) 2004-12-01
AU2004208483B2 (en) 2008-03-06
PA8594601A1 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
NO20044442L (no) Fosfatprodroger av fluoroksindoler
DE50202573D1 (en) Pyrazolylsubstituierte thienyloxy-pyridine
NO20080051L (no) Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme
IN2014DN08578A (de)
NO20051273L (no) Piperidinylforbindelser som selektivt binder integriner
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
HRP20050803B1 (hr) Novitetna kristalna modifikacija anhidrata boskalida
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
ATE295841T1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
TW200700007A (en) N-(4-pyridyl)methylsulfonamides for combating arthropodal pests
NO20053431L (no) Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.
NO20053312L (no) Benzofuranderivat.
GB0412314D0 (en) Compounds
BRPI0400354A (pt) Composição microbicida, e, composição de tinta
TWI318625B (en) Process for the preparation of 2-aminomethylpyridine derivative
DOP2004000808A (es) Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetilfenil)-n-[6-(1,1-dioxo-1 6-tiomorfolin-4-il)-4-(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida
PT755393E (pt) Novas formas cristalinas de 1-¬5-metanossulfonamidoimdolil-2-carbonil|-4-¬3-(1-metiletilamino)-2-piridinil|piperazina
WO2005049589A3 (en) Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
PL1601361T3 (pl) Pirydylosulfonamido-pirymidyny do leczenia nefropatii cukrzycowej
WO2004069790A3 (en) Crystalline modifications of triazinylaminostilbenes
ATE338759T1 (de) 2-(aminomethyl)tetrahydro-9-oxa-1,3- diazacyclopentaca)naphthalinylderivate mit antipsychotischer wirkung
HK1076257A (en) 4-(2,4-dichloro-5-methoxyphenyl)amino-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application